Physician profile
Pierre Minerva
NPI 1699708099
$13,670.19
in general payments reported to CMS, 2019-2025
53 companies · $2,261 in 2025
The $2,261 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,979 · 2020: $1,292 · 2021: $1,470 · 2022: $2,069 · 2023: $2,210 · 2024: $2,389 · 2025: $2,261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,829 · Education: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,829.47 |
| Education | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,914.44 | 2019-2025 | |
| Amgen INC. | $1,820.71 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Astrazeneca Pharmaceuticals LP | $879.41 | 2021-2025 | Saphnelo, Fasenra |
| Ucb, INC. | $854.72 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $702.64 | 2019-2025 | |
| Genentech USA, INC. | $652.44 | 2019-2025 | Actemra, Rituxan |
| Janssen Biotech, INC. | $559.20 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $515.87 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $430.04 | 2019-2024 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.75 | 2019-2024 | Cyltezo, Spevigo |
| Ani Pharmaceuticals, INC. | $373.75 | 2022-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $365.09 | 2019-2025 | Orencia |
| Lilly USA, LLC | $323.62 | 2019-2025 | Taltz |
| Radius Health, INC. | $306.16 | 2019-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $268.77 | 2023-2025 | Idacio, Tyenne |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Minerva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.